The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Treatment options for patients with R/R DLBCL who progress after CAR-T and bispecifics
Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, discusses challenges in treating patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who progress after bispecific and CAR-T therapies. Dr Alderuccio highlights the potential of new agents, such as CELMoDs and newer bispecifics, as well as in vivo CAR-T, to address this gap. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
